In the context of high levels of response now being obtained in mantle cell lymphoma (MCL) with modern induction and maintenance regimens, there is no advantage in adding autologous hematopoietic cell transplant (aHCT) when patients have become minimal residual disease (MRD)-negative at the level of 1 malignant cell or less in 1,000,000 lymphocytes (uMRD-6), according to to a new study.
In a four-arm phase 3 trial that enrolled patients who achieved uMRD-6, rituximab maintenance alone